|drug1745||Home Sleep Apnea Testing or In-hospital Polysomnography Wiki||0.45|
|drug195||Acetazolamide + supplemental oxygen + PAP therapy Wiki||0.45|
|drug3642||Skin biopsy Wiki||0.45|
|D012891||Sleep Apnea, NIH||1.00|
|D020181||Sleep Apnea, Obstructive NIH||0.80|
|D020182||Sleep Apnea, Central NIH||0.45|
|D053120||Respiratory Aspiration NIH||0.11|
|D009103||Multiple Sclerosis NIH||0.11|
|D040921||Stress Disorders, Traumatic NIH||0.08|
|D013313||Stress Disorders, Post-Traumatic NIH||0.07|
There are 5 clinical trials
Approximately 20 million Americans suffer from Obstructive Sleep Apnea (OSA) creating risks for major health problems, including dementia, heart attack, and stroke. Obesity, a growing problem for Americans and Veterans alike, is the greatest risk factor for the development of OSA. Male gender and smoking, other OSA risk factors, are common in Veterans. Given the high comorbidity of these risk factors in Veterans, OSA presents a significant health burden to Veterans. The investigators' prior work provides evidence that OSA occurs in up to 69% of Vietnam-era Veterans with PTSD. OSA is easily treated; however, 15-30% of OSA patients are non-compliant with continuous positive airway pressure (CPAP), the standard OSA treatment. The proposed research aims to facilitate adherence to CPAP treatment by testing a novel cognitive-behavioral therapy intervention in Veterans with PTSD. If successful, it may represent an approach that could be applied to the rehabilitation of other chronic conditions with similar barriers to care.
Description: The CPAP machine will measure the number of hours that the CPAP mask is on the participant's face and in use.Measure: Time in hours of "mask-on" CPAP usage per night Time: 1 year
Description: Effect of CBT on Self-reported Everyday Activities, Mood and Quality of Life. The investigators hypothesize that after initiating CPAP treatment, Veterans in the CBT-OSA group will report more improvement in the ease of performing everyday activities compared to that reported by those in the Education group.Measure: Functional Outcomes of Sleep Questionnaire (FOSQ) Time: 1 year
Description: Effect of CBT on Cognitive Outcomes. The CBT-OSA group will have better cognitive outcomes than the Education group over time. The California Verbal Learning Test-II, Delayed Recall Score is the cognitive outcome measure.Measure: California Verbal Learning Test, Second Edition (CVLT-II) Time: 1 year
Description: Effect of CBT on PTSD. The CBT-OSA group will have fewer PTSD symptoms than the Education group over time. The PTSD Checklist for DSM-5 (PCL-5) will be the PTSD outcome measure.Measure: PTSD Checklist for DSM-5 (PCL-5) Time: 1 year
Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.
Description: CO2 reserve is the requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative.Measure: CO2 reserve Time: 120 days
Description: Central apnea indices is used to indicate the severity of central sleep apneaMeasure: Central apnea indices Time: 120 days
Description: Controller gain is a ventilatory response to changes in end-tidal PCO2Measure: Controller gain Time: 120 days
Description: Plant gain is blood gas response to a change in ventilation. This measure represents the effectiveness of the "plant" in eliminating CO2.Measure: Plant gain Time: 120 days
Description: This measure represents the activity of the carotid bodies. It is measured by the decrease in ventilation in response to a single breath of 100% oxygen.Measure: Carotid body function Time: 120 days
Description: Peripheral chemoreflex sensitivity is measured either via brief hypoxia or a single breath of CO2.Measure: Peripheral chemoreflex sensitivity Time: 120 days
Description: The nadir pressure in the upper airway (supra-glottic pressure) prior to the occurrence of an arousal.Measure: Respiratory arousal threshold Time: 120 days
Description: To assess breathing stability, the investigators will measure % stable breathing using minute ventilation (VE) and tidal volume (VT) coefficient of variation as indices of breathing instability.Measure: % stable breathing Time: 120 days
Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scaleMeasure: The rate of clinical improvement Time: 7 days
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scaleMeasure: The rate of clinical improvement Time: 14 days
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scaleMeasure: The rate of clinical improvement Time: 21 days
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scaleMeasure: The rate of clinical improvement Time: 28 days
Description: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortalityMeasure: Clinical status - improvement Time: 7, 14, 21, 28 days
Description: Defined as an increase in category on a 7-category ordinal scale from admissionMeasure: Clinical status - worsening Time: 7, 14, 21, 28 days
Description: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.Measure: Long-term outcomes Time: 4-6 months after the initial hospital admission
As long as the people stay at home because of the Covid 19 outbreak, the investigators assume that the sleep quality of OUAS patients, like everyone else, and the sleep quality of COVID-19 outbreak are reduced due to anxiety and anxiety in people. In addition, we assume that sleep quality and physical activity level are related to health literacy level and fear of movement (kinesiophobia). In this study; the investigators aimed to determine how patients are affected by this process by evaluating sleep quality, physical activity, fear of movement and health literacy in OSAS patients during our stay in the COVID-19 outbreak.
Description: International Physical Activity Questionnaire/ In activity-specific scoring, walking under the heading of the fields is calculated by the sum of the moderate intensity activity and intensive activity in itself. From these calculations, a score is obtained in MET-minutes. There are 3 categories of physical activity level classification. Physical activity levels are classified as physically inactive (inactive), low level of physical activity (minimally active) and sufficient level of physical activity (very active)Measure: Physical Activity Time: 1 day
Description: The Pittsburgh Sleep Quality IndexMeasure: Sleep Quality Time: 1 day
Description: In order to measure the general sleepiness of people during the day, it was evaluated with a standard questionnaire, which is defined as Epworth sleepiness scale (EUS) and consists of 8 questions. The answers for each question are scored between 0 and 3 and the total score is obtained. The score obtained above 10 in EUS has high sensitivity and specificity for daytime sleepiness.Measure: Daytime Sleepiness Time: 1 day
Description: Tampa Kinesiophobia Scale (TKS)The person gets a total score between 17-68. The high score on the scale indicates that kinesiophobia is also highMeasure: Fear of movement Time: 1 day
Description: Translated into Turkish TURKEY health literacy SCALE-32 (Tsoy-32) will be used. It was used to evaluate the literacy rates of individuals over the age of 15. 0 indicates the lowest health literacy and 50 indicates the highest health literacy.Measure: Health literacy Time: 1 day
Description: In the human circadian rhythm, the Morning Morning-Evening Survey (SAA) form was used, which determined morning and evening types.Measure: Circadian rhythm evaluation Time: 1 day
This study will evaluate the influence of sleep apnea on clinical and radiological features of MS. Sleep apnea is associated with hypoxemia during sleep, which we believe is detrimental to MS. We will examine clinical data (MRI, lab results, medical history, labs, and sleep studies) of Dr. Sloane's MS patients. This will allow us to study correlations between MRI, clinical data, lab studies and sleep studies. We are specifically interested in the type of sleep apnea associated with MS, and whether MRI or clinical metrics of MS severity correlate with presence or absence of sleep apnea.
Description: Home Sleep Study DataMeasure: Home Sleep Study Data Time: 1 year
Description: sleep quality, quality of life, depression and anxiety scalesMeasure: Questionnaire data Time: 1 year
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports